DK1556489T3 - Farmaceutisk sammensætning til fremstilling af et lægemiddel til behandling og/eller forebyggelse af en patologi i forbindelse med obsessiv-kompulsiv forstyrrelse eller obesitet - Google Patents

Farmaceutisk sammensætning til fremstilling af et lægemiddel til behandling og/eller forebyggelse af en patologi i forbindelse med obsessiv-kompulsiv forstyrrelse eller obesitet

Info

Publication number
DK1556489T3
DK1556489T3 DK03767876.0T DK03767876T DK1556489T3 DK 1556489 T3 DK1556489 T3 DK 1556489T3 DK 03767876 T DK03767876 T DK 03767876T DK 1556489 T3 DK1556489 T3 DK 1556489T3
Authority
DK
Denmark
Prior art keywords
prevention
treatment
pharmaceutical composition
obsessive
obesity
Prior art date
Application number
DK03767876.0T
Other languages
English (en)
Inventor
Valerie Compan
Original Assignee
Centre Nat Rech Scient
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre Nat Rech Scient filed Critical Centre Nat Rech Scient
Application granted granted Critical
Publication of DK1556489T3 publication Critical patent/DK1556489T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Anesthesiology (AREA)
  • Diabetes (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
DK03767876.0T 2002-10-31 2003-10-31 Farmaceutisk sammensætning til fremstilling af et lægemiddel til behandling og/eller forebyggelse af en patologi i forbindelse med obsessiv-kompulsiv forstyrrelse eller obesitet DK1556489T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0213725A FR2846559B1 (fr) 2002-10-31 2002-10-31 Composition pharmaceutique pour la preparation d'un medicament destine a traiter et/ou a prevenir une pathologie liee a une conduite obsessionnelle
PCT/FR2003/003262 WO2004042063A1 (fr) 2002-10-31 2003-10-31 Composition pharmaceutique pour la preparation d'un medicament destine a traiter et/ou a prevenir une pathologie liee a une conduite obsessionnelle ou l'obesite

Publications (1)

Publication Number Publication Date
DK1556489T3 true DK1556489T3 (da) 2011-05-16

Family

ID=32104388

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03767876.0T DK1556489T3 (da) 2002-10-31 2003-10-31 Farmaceutisk sammensætning til fremstilling af et lægemiddel til behandling og/eller forebyggelse af en patologi i forbindelse med obsessiv-kompulsiv forstyrrelse eller obesitet

Country Status (12)

Country Link
US (3) US8859537B2 (da)
EP (1) EP1556489B1 (da)
JP (1) JP4852245B2 (da)
AT (1) ATE497003T1 (da)
AU (1) AU2003292310A1 (da)
CA (1) CA2503546C (da)
DE (1) DE60335892D1 (da)
DK (1) DK1556489T3 (da)
ES (1) ES2362092T3 (da)
FR (1) FR2846559B1 (da)
PT (1) PT1556489E (da)
WO (1) WO2004042063A1 (da)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2846559B1 (fr) * 2002-10-31 2007-06-15 Centre Nat Rech Scient Composition pharmaceutique pour la preparation d'un medicament destine a traiter et/ou a prevenir une pathologie liee a une conduite obsessionnelle
US20060204599A1 (en) * 2005-03-14 2006-09-14 Wheat Jared R Dietary supplement and method of using same
ES2705027T3 (es) 2010-08-19 2019-03-21 Buck Institute For Age Res Métodos de tratamiento del deterioro cognitivo leve (DCL) y trastornos relacionados
WO2019094757A1 (en) 2017-11-09 2019-05-16 The Trustees Of Columbia University In The City Of New York Pharmacological prophylactics against stress-induced affective disorders in females
US11622948B2 (en) 2017-11-09 2023-04-11 The Trustees Of Columbia University In The City Of New York Biomarkers for efficacy of prophylactic treatments against stress-induced affective disorders
FR3093419B1 (fr) * 2019-03-08 2021-06-18 Univ Grenoble Alpes Composition et procédé associé de mesure de l’observance thérapeutique
CN113924087A (zh) * 2019-04-09 2022-01-11 纽约市哥伦比亚大学理事会 血清素4受体激动剂对抗应激的预防功效
CN115581201A (zh) * 2022-08-26 2023-01-10 云南省农业科学院花卉研究所 以茎段为外植体诱导的二倍体月季f1-61的植株再生方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ258320A (en) * 1992-11-03 1996-12-20 Synaptic Pharma Corp Dna encoding a human receptor 5-ht4b receptor and diagnostic use
US5472866A (en) * 1992-12-24 1995-12-05 Synaptic Pharmaceutical Corporation DNA encoding 5-HT4A serotonin receptors
ES2208870T3 (es) * 1996-02-15 2004-06-16 Janssen Pharmaceutica N.V. Uso de antagonistas del receptor 5ht4 para resolver los efectos gastrointestinales de los inhibidores de la reabsorcion de serotonina.
WO2000064441A2 (en) * 1999-04-28 2000-11-02 Respiratorius Ab Compound for use as a medicament for treatment of disorders involving bronchocontraction
GB9913850D0 (en) * 1999-06-14 1999-08-11 Janssen Pharmaceutica Nv Cloning and expression of a novel receptor
FR2811989A1 (fr) * 2000-07-18 2002-01-25 Sanofi Synthelabo Derives de polyfluoroalkytriazole, leur preparation et leur application en therapeutique
FR2846559B1 (fr) * 2002-10-31 2007-06-15 Centre Nat Rech Scient Composition pharmaceutique pour la preparation d'un medicament destine a traiter et/ou a prevenir une pathologie liee a une conduite obsessionnelle

Also Published As

Publication number Publication date
US20090124592A1 (en) 2009-05-14
FR2846559B1 (fr) 2007-06-15
EP1556489A1 (fr) 2005-07-27
JP2006520319A (ja) 2006-09-07
PT1556489E (pt) 2011-05-31
CA2503546C (fr) 2014-02-11
JP4852245B2 (ja) 2012-01-11
US8436021B2 (en) 2013-05-07
US8859537B2 (en) 2014-10-14
WO2004042063A8 (fr) 2005-08-11
US20130274293A1 (en) 2013-10-17
ATE497003T1 (de) 2011-02-15
US20060116341A1 (en) 2006-06-01
FR2846559A1 (fr) 2004-05-07
DE60335892D1 (de) 2011-03-10
EP1556489B1 (fr) 2011-01-26
CA2503546A1 (fr) 2004-05-21
WO2004042063A1 (fr) 2004-05-21
AU2003292310A1 (en) 2004-06-07
ES2362092T3 (es) 2011-06-28
US9168250B2 (en) 2015-10-27

Similar Documents

Publication Publication Date Title
BR0312785A (pt) Tratamento de desordens relacionadas a tnf(alfa)
MX2007006204A (es) Combinaciones que comprenden inhibidores de jak y cuando menos uno de entre inhibidores de bcr-abl, flt-3, fak o raf cinasa.
DK1412357T3 (da) Beta-aminotetrahydroimidazo-(1,2-a)-pyraziner og tetrahydrotriazolo-(4,3-a)-pyraziner som dipeptidylpeptidaseinhibitorer til behandling eller forebyggelse af diabetes
DK1656372T3 (da) 2,4-pyrimidindiaminforbindelser til anvendelse til behandling eller forebyggelse af autoimmunsygdomme
BRPI0411743A (pt) método e composições para tratar doenças relacionadas a amilóides
PL371736A1 (en) Method for administering glp-1 molecules
DK1427409T3 (da) Fremgangsmåde til behandling eller forhindring af vaskulær inflammation under brug af en eller flere sterolabssorptionsinhibitorer
NO20072352L (no) Forbindelser og sammensetninger som inhibitorer av cannabinoidreceptor 1-aktivitet
EA200601552A1 (ru) Замещенные конденсированные гетероциклические с-гликозиды
DK1651161T3 (da) Farmaceutiske præparater og fremgangsmåder til at fremme sårheling
SG130189A1 (en) Substituted indole-o-glucosides
EA200900802A1 (ru) Способы и композиции для лечения амилоидных заболеваний
IS8071A (is) Aðferð við meðhöndlun á hnútahersli, fitudreyra og tengdum ástands tegundum og lyfjafræðilegum samsetningum
UA87991C2 (en) Substituted indole-o-glucosides
DK1237575T3 (da) TNF-alfa-antagonist og LFA-1-antagonist til behandling af rheumatoid arthritis
BRPI0409523A (pt) método para o tratamento da dor neuropática, método de identificação de um composto e composição farmacêutica
DK1505990T3 (da) Fremgangsmåder til behandling af hepatitis
NO20045354L (no) Fremgangsmater for behandling av angiogenese, turmorvekst og metastaser
DK1596868T3 (da) Fremgangsmåde til behandling af hjertesvigt og medikament dertil
DK1556489T3 (da) Farmaceutisk sammensætning til fremstilling af et lægemiddel til behandling og/eller forebyggelse af en patologi i forbindelse med obsessiv-kompulsiv forstyrrelse eller obesitet
NO20075321L (no) Fremgangsmate for bronnbehandling og konstruksjon
DK1802749T3 (da) KASPP (LRRK2)-gen, dets fremstilling og anvendelse til påvisning og behandling af neurodegenerative lidelser
NO20052655L (no) Sammensmeltede heterocykliske forbindelser
BRPI0411168A (pt) composição para o tratamento dos cabelos, usos de uma composição e método de tratamento dos cabelos
ATE446299T1 (de) Verfahren zur herstellung von 7-ethyl-10- hydroxycamptothecin